Evidence map›Paper›PMID 36969367›Full record

ArticleClinical & translational immunology2023

A specific anti-COVID-19 BNT162b2 vaccine-induced early innate immune signature positively correlates with the humoral protective response in healthy and multiple sclerosis vaccine recipients.

Martina Severa, Fabiana Rizzo, Alessandro Sinigaglia, Daniela Ricci, Marilena Paola Etna, Gaia Cola, Doriana Landi, Maria Chiara Buscarinu, Catia Valdarchi, Giovanni Ristori and 10 more

Open access · goldAbstract read
In one paragraph

Article in Clinical & translational immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 1 country.

Martina SeveraDepartment of Infectious Disease Istituto Superiore di Sanità Rome Italy.ORCID https://orcid.org/0000-0002-0411-4545
Fabiana RizzoDepartment of Infectious Disease Istituto Superiore di Sanità Rome Italy.ORCID https://orcid.org/0000-0001-9748-4571
Alessandro SinigagliaDepartment of Molecular Medicine University of Padova Padua Italy.ORCID https://orcid.org/0000-0002-2386-1757
Daniela RicciDepartment of Infectious Disease Istituto Superiore di Sanità Rome Italy.ORCID https://orcid.org/0000-0002-8445-512X
Marilena Paola EtnaDepartment of Infectious Disease Istituto Superiore di Sanità Rome Italy.ORCID https://orcid.org/0000-0003-2551-393X
Gaia ColaDepartment of Systems Medicine MS center Tor Vergata University Rome Italy.ORCID https://orcid.org/0000-0003-2050-0806
Doriana LandiDepartment of Systems Medicine MS center Tor Vergata University Rome Italy.ORCID https://orcid.org/0000-0002-3309-8417
Maria Chiara BuscarinuCenter for Experimental Neurological Therapies Sant'Andrea Hospital Rome Italy.ORCID https://orcid.org/0000-0002-4839-1528
Catia ValdarchiDepartment of Infectious Disease Istituto Superiore di Sanità Rome Italy.ORCID https://orcid.org/0000-0002-4764-3180
Giovanni RistoriCenter for Experimental Neurological Therapies Sant'Andrea Hospital Rome Italy.ORCID https://orcid.org/0000-0002-6598-6777
Silvia RiccettiDepartment of Molecular Medicine University of Padova Padua Italy.ORCID https://orcid.org/0000-0002-3153-5062
Chiara PiubelliDepartment of Infectious-Tropical Diseases and Microbiology IRCCS Sacro Cuore Don Calabria Hospital Negrar di Valpolicella Italy.ORCID https://orcid.org/0000-0002-5739-3795
Pierangela PalmeriniDepartment of Surgery, Oncology and Gastroenterology, Immunology and Oncology Section University of Padova Padua Italy.ORCID https://orcid.org/0000-0003-4446-8193
Antonio RosatoDepartment of Surgery, Oncology and Gastroenterology, Immunology and Oncology Section University of Padova Padua Italy.ORCID https://orcid.org/0000-0002-5263-8386
Federico GobbiDepartment of Infectious-Tropical Diseases and Microbiology IRCCS Sacro Cuore Don Calabria Hospital Negrar di Valpolicella Italy.ORCID https://orcid.org/0000-0002-6899-4545
Stefano BalducciMetabolic Fitness Association Rome Italy.ORCID https://orcid.org/0000-0001-8128-3863
Girolama Alessandra MarfiaDepartment of Systems Medicine MS center Tor Vergata University Rome Italy.ORCID https://orcid.org/0000-0001-5863-7758
Marco SalvettiCenter for Experimental Neurological Therapies Sant'Andrea Hospital Rome Italy.ORCID https://orcid.org/0000-0002-0501-8803
Luisa BarzonDepartment of Molecular Medicine University of Padova Padua Italy.ORCID https://orcid.org/0000-0003-0720-8456
Eliana Marina CocciaDepartment of Infectious Disease Istituto Superiore di Sanità Rome Italy.ORCID https://orcid.org/0000-0002-1606-2949
Istituto Superiore di Sanità · ITUniversity of Padua · ITUniversity of Rome Tor Vergata · ITCTO Andrea Alesini · ITOspedale Sacro Cuore Don Calabria · ITIstituto Neurologico Mediterraneo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The very rapidly approved mRNA-based vaccines against SARS-CoV-2 spike glycoprotein, including Pfizer-BioNTech BNT162b2, are effective in protecting from severe coronavirus disease 2019 (COVID-19) in immunocompetent population. However, establishing the duration and identifying correlates of vaccine-induced protection will be crucial to optimise future immunisation strategies. Here, we studied in healthy vaccine recipients and people with multiple sclerosis (pwMS), undergoing different therapies, the regulation of innate immune response by mRNA vaccination in order to correlate it with the magnitude of vaccine-induced protective humoral responses. Methods: Healthy subjects ( Results: We identified an early immune module composed of the IFN-inducible genes Mx1, OAS1 and IRF1, the serum cytokines IL-15, IL-6, TNF-α and IFN-γ and the chemokines IP-10, MCP-1 and MIG, induced 1 day post second and third BNT162b2 vaccine doses, strongly correlating with magnitude of humoral response to vaccination in healthy and MS vaccinees. Moreover, induction of the early immune module was dramatically affected in pwMS treated with fingolimod and ocrelizumab, both groups unable to induce a protective humoral response to COVID-19 vaccine. Conclusion: Overall, this study suggests that the vaccine-induced early regulation of innate immunity is mediated by IFN signalling, impacts on the magnitude of adaptive responses and it might be indicative of vaccine-induced humoral protection.

Indexed as

humoral responseinnate immunitymRNA vaccineSARS‐CoV‐2

Identifiers

PMID36969367
PMCPMC10036198
OpenAlexW4360763096

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.